The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
First drug to modestly slow Alzheimer’s cognitive decline, based on 1,800 patients.
The FDA Advisory Committee’s endorsement of Leqembi paves way for traditional approval, ushers in a new era for Alzheimer’s
The FDA has approved the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for the treatment of agitation associated with Alzheimer’s. It’s the first such treatment to be approved in the US. Learn more.
Eli Lilly Company’s TRAILBLAZER-ALZ 2 Phase 3 study shows that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Learn more.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
VIDEO + ARTICLE: Phase II/III trials are begining in the Tau NextGen study. The study will assess the effect of Lecanemab, an experimental anti-amyloid therapy,
OLD-NEW DRUG RESEARCH: The diuretic bumetanide, used for more than 30 years to treat hypertension and heart failure, was also found to reverse signs of
VIDEO + ARTICLE: An experimental drug produced by Annovis has received its generic name following successful completion of its Phase II trials. Buntanetap is intended
Even in later life, quitting smoking significantly reduces dementia risk.
New research published in The Lancet offers renewed hope — it’s never too late to protect your brain.
Some everyday medicines may nudge dementia risk higher — but safer, equally effective alternatives often exist. Here’s how to replace high-risk drugs with brain-friendlier options
A simple blood test was newly approved, replacing spinal taps and brain scans for ruling out Alzheimer’s. The FDA has just cleared Roche’s Elecsys® pTau181 — the first test shown to rule out Alzheimer’s with 98% accuracy, offering peace of mind and earlier answers for millions.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
No spam, only news and updates.
